UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 16.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 198,642 shares of the life sciences company's stock after acquiring an additional 28,457 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.26% of Integra LifeSciences worth $4,505,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Soleus Capital Management L.P. bought a new position in shares of Integra LifeSciences during the 4th quarter valued at about $28,940,000. Lord Abbett & CO. LLC raised its stake in shares of Integra LifeSciences by 86.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock worth $30,210,000 after acquiring an additional 618,773 shares in the last quarter. Norges Bank bought a new stake in shares of Integra LifeSciences in the 4th quarter worth approximately $8,967,000. Systematic Financial Management LP boosted its stake in shares of Integra LifeSciences by 40.7% in the 4th quarter. Systematic Financial Management LP now owns 860,563 shares of the life sciences company's stock valued at $19,518,000 after purchasing an additional 248,817 shares in the last quarter. Finally, Access Investment Management LLC bought a new position in shares of Integra LifeSciences during the 4th quarter valued at $4,416,000. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART traded up $0.32 during midday trading on Friday, reaching $13.61. 434,588 shares of the company's stock traded hands, compared to its average volume of 1,033,863. Integra LifeSciences Holdings Co. has a one year low of $11.60 and a one year high of $32.66. The stock has a 50 day moving average of $15.33 and a 200 day moving average of $20.66. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -151.46, a P/E/G ratio of 0.73 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. During the same quarter in the prior year, the firm earned $0.55 earnings per share. The business's revenue was up 3.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IART. Truist Financial reduced their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. JMP Securities cut their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Wells Fargo & Company lowered their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences has an average rating of "Hold" and a consensus target price of $18.63.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.